Verve Therapeutics, Inc.
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067
info@portnoylaw.com
Verve Therapeutics is a clinical-stage company focused on developing gene editing treatments for cardiovascular diseases. During the Class Period, the company was involved in the Heart-1 Phase 1b clinical trial of VERVE-101, a new investigational gene editing medicine designed to permanently deactivate the PCSK9 gene in the liver, aiming to lower harmful LDL cholesterol levels.
The class action lawsuit against Verve Therapeutics claims that the defendants made false or misleading statements and failed to disclose important information, specifically: (i) they did not fully reveal the reasons for potentially halting the Heart-1 trial; and (ii) they exaggerated the benefits of their proprietary lipid nanoparticles (LNP) delivery system.
Additionally, the lawsuit states that on April 2, 2024, Verve Therapeutics announced that the Heart-1 trial would be stopped due to an adverse event in a participant who received a 0.45 mg/kg dose of VERVE-101, attributing the issue to the LNP delivery system. Following this announcement, Verve Therapeutics’ stock price dropped nearly 35%.
